Received Oct 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 37F34 | — |
Received 2 doses; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 37F34, expiry date 24-OCT-2027) for prophylaxis. Previously administered products included Boostrix (received 1st dose in 12-JUL-2024). On 25-SEP-2025, the patient received the 2nd dose of Boostrix. On 25-SEP-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: Received 2 doses ). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-SEP-2025 The nurse reported that she had a student that gave the Boostrix vaccine to, and he actually, already had one on 12-JUL-2024, which led to extra dose administered. So it was not due to another one yet.